None listed
Conditions
Interventions
Drug : This is a single-center center, open-label, randomized comparison trial. All patients will be treated according to current guideline recommendation including statins, antihypertensive medicatio
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Men or women at least 18 years of age 2) Patients undergoing CABG with the use of 1 or more SVGs 3) The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
Exclusion criteria
Exclusion criteria: 1) A known intolerance to a study drug (aspirin, clopidogrel) 2) Patients who will have valve or aorta surgery simultaneously. 3) History of hemorrhagic stroke or known structural cerebral vascular lesion (AV malformation, aneurysm, etc) 4) Patients requiring long-term oral anticoagulants or dual antiplatelet therapy 5) Persistent thrombocytopenia (platelet count <100,000/?l) 6) Chronic kidney disease (eGFR<30ml/min/1.73m2) 7) Inability to undergo coronary computed tomography angiography, in the investigator's opinion, for instance due to severe claustrophobia or contrast allergy 8) Current treatment for the active cancer 9) Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study. 10)Unwillingness or inability to comply with the procedures described in this protocol. 11) Patient’s pregnant or breast-feeding or child-bearing potential. 12) Patients who had CPCR due to cardiac arrest or ECHMO due to critical heart failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of occlusion of SVG using Coronary artery CT at the time of 12months after the randomization. | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of non-fatal MI, Stroke, coronary induced death within 12months after the randomization.;All-cause death and revascularization within 12months after the randomization.;Bleeding classified by Thrombolysis In Myocardial Infarction (TIMI) within 12months after the randomization. | — |
Countries
Korea, Republic of
Contacts
Public ContactYU KYUNH CHOI
Asan Medical Center
Outcome results
None listed